Neuren Pharmaceuticals (NEU) has received ethics approval to proceed with the phase two clinical study of a treatment for Angelman syndrome in Australia. Angelman syndrome is defined by significant developmental delay and learning difficulties, which manifest as….Read More

Ethical approval on Neuren Pharmaceuticals’ Angelman drug study.

New Malaria Drug Candidate MMV367 Shows Rapid Parasite Killing and Hope Against Drug Resistance

Canada-U.S. Trade War Hits Wine Industry as California Producers Push for End to Alcohol Boycott

Beyond an Airport: Sri Lanka’s Bold Vision to Turn BIA into a World-Class Aviation Gateway by 2055

Modi’s Australia visit is a major boost for India-Australia relations: The strategic moves revealed!

Glasgow 2026 Commonwealth Games to Showcase Record Para-Sport Opportunities as Athletes Chase More Medals

Related Articles

New Malaria Drug Candidate MMV367 Shows Rapid Parasite Killing and Hope Against Drug Resistance

Study Finds Medicinal Cannabis Compound Could Expand Treatment Options for Drug-Resistant Childhood Epilepsy

Colon Cancer in Young Adults: Why Cases Are Climbing

Could This New Test Make Monitoring Babies’ Health Easier?

Scientists Discover New Brain Regions Linked to Language Comprehension Beyond Classic Language Centers

BRICS expansion: five countries join, another 25 to follow in 2024

Chinese state media lauds India’s achievements under PM Modi!

Security alarm for India: Bangladesh frees Al-Qaeda terror group chief